Evidence map›Paper›PMID 35200634›Full record

Trial reportMarine drugs2022

A

Fabien Havas, Shlomo Krispin, Moshe Cohen, Estelle Loing, Morgane Farge, Thierry Suere, Joan Attia-Vigneau

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Marine drugs, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 34 citations in OpenAlex.

  1. Review
  2. Review
  3. Pharmaceutics · 2026
    Article
  4. Article
  5. Review
  6. Microalgae: revolutionizing skin repair and enhancement.Biotechnology reports (Amsterdam, Netherlands) · 2025
    Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. The Ocean's Pharmacy: Health Discoveries in Marine Algae.Molecules (Basel, Switzerland) · 2024
    Review
  13. Review
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Fabien HavasInternational Flavors & Fragrances-Lucas Meyer Cosmetics, Faran 4, Yavne 8122503, Israel.
Shlomo KrispinInternational Flavors & Fragrances-Lucas Meyer Cosmetics, Faran 4, Yavne 8122503, Israel.ORCID 0000-0003-0747-1174
Moshe CohenInternational Flavors & Fragrances-Lucas Meyer Cosmetics, Faran 4, Yavne 8122503, Israel.
Estelle LoingInternational Flavors & Fragrances, 521 West 57th Street, New York, NY 10019, USA.
Morgane FargeInternational Flavors & Fragrances-Lucas Meyer Cosmetics, 195 Route d'Espagne, 31 036 Toulouse, France.
Thierry SuereInternational Flavors & Fragrances-Lucas Meyer Cosmetics, 195 Route d'Espagne, 31 036 Toulouse, France.
Joan Attia-VigneauInternational Flavors & Fragrances-Lucas Meyer Cosmetics, 195 Route d'Espagne, 31 036 Toulouse, France.ORCID 0000-0002-5728-0926
International Flavors & Fragrances (France) · FRInternational Flavors & Fragrances (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glycation, and the resulting buildup of advanced glycation end products (AGEs), is recognized as a key driver of cumulative skin damage and skin aging.

Indexed as

AdultAnti-Inflammatory AgentsBiological ProductsDouble-Blind MethodFemaleGlycation End Products, AdvancedHistamineHumansMicroalgaeMiddle AgedSkin AgingAnti-Inflammatory AgentsBiological ProductsGlycation End Products, AdvancedHistaminealgaeantiagingcarotenoidDunaliellaglycationinflammationphytoenephytoflueneskin agingsun care

Identifiers

PMID35200634
PMCPMC8879334
OpenAlexW4210620886

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.